Elucida Oncology, Inc.™ is a biotechnology company focused on the development of life-changing therapeutics based on C’Dots, our novel, ultra-small cancer drug delivery platform. C’Dot-Drug-Conjugates, or CDC’s, are novel therapeutics that can substantially increase the concentration of highly potent cytotoxic drugs inside difficult to treat tumors with reduced systemic exposure due to their unique Target or Clear properties.
We have an ongoing research partnership with the Michelle Bradbury Lab at MSKCC. This partnership supports research services and the continued development of clinical applications for our Target or Clear™ C-Dot platform, preclinical testing and early-stage clinical trial support.
We have an ongoing research partnership with the Wiesner Group at Cornell University. This partnership supports research services and the continued development of our Target or Clear™ C-Dot platform to accommodate evolving clinical uses and diverse biologic needs.
The MSKCC-Cornell Center for Translation of Nanomedicines is a National Cancer Institute (NCI) funded Center for Cancer Nanotechnology. This partnership supports further advancements and clinical translation of a suite of products based on C-Dot technology.
